Structural features of antiviral APOBEC3 proteins are linked to their functional activities

Frontiers in Microbiology

Volumn 2, Issue DEC, 2011, Pages

  Kitamura, Shingo ^a,b   Ode, Hirotaka ^a   Iwatani, Yasumasa ^a,c  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

APOBEC3; APOBEC3G; Cytidine deaminase; HIV; Retrovirus; Structure; Ubiquitin; Vif

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84867230091     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2011.00258     Document Type: Review

References (41)

1. Albin, J. S., and Harris, R. S. (2010). Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev. Mol. Med. 12, e4.
2. Albin, J. S., LaRue, R. S., Weaver, J. A., Brown, W. L., Shindo, K., Har-jes, E., Matsuo, H., and Harris, R. S. (2010). A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif. J.Biol Chem. 285, 40785-40792.
3. Binka, M., Ooms, M., Steward, M., and Simon, V. (2011). The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F and APOBEC3H. J. Virol. (in press).
4. Bogerd, H. P., Doehle, B. P., Wiegand, H. L., and Cullen, B. R. (2004). A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U.S.A. 101, 3770-3774.
5. Chen, G., He, Z., Wang, T., Xu, R., and Yu, X. F. (2009). A patch of positively charged amino acids surrounding the human immunodeficiency virus type 1 Vif SLVx4Yx9Y motif influences its interaction with APOBEC3G. J. Virol. 83,8674-8682.
6. Chen, K. M., Harjes, E., Gross, P. J., Fahmy, A., Lu, Y., Shindo, K., Harris, R. S., and Matsuo, H. (2008). Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 452, 116-119.
7. Dang, Y., Siew, L. M., Wang, X., Han, Y., Lampen, R., and Zheng, Y H. (2008a). Human cytidine deaminase APOBEC3H restricts HIV-1 replication. J. Biol. Chem. 283, 11606-11614.
8. Dang, Y., Siew, L. M., and Zheng, Y H. (2008b) APOBEC3G is degraded by the proteasomal pathway in a Vif-dependent manner without being polyubiquitylated. J. Biol. Chem. 283, 13124-13131.
9. Furukawa,A.,Nagata, T.,Matsugami,A., Habu, Y., Sugiyama, R., Hayashi, F., Kobayashi, N., Yokoyama, S., Takaku, H., and Katahira, M. (2009). Structure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3G. EMBOJ. 28, 440-451.
10. Goila-Gaur, R., and Strebel, K. (2008). HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5, 51.
11. Harari, A., Ooms, M., Mulder, L. C., and Simon, V (2009). Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H. J. Virol. 83, 295-303.
12. He, Z., Zhang, W., Chen, G., Xu, R., and Yu, X. F. (2008). Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction. J. Mol. Biol. 381, 1000-1011.
13. Holden, L. G., Prochnow, C., Chang, Y P., Bransteitter, R., Chelico, L., Sen, U., Stevens, R. C., Goodman, M. F., and Chen, X. S. (2008). Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature 456, 121-124.
14. Huthoff, H., and Malim, M. H. (2007). Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encap-sidation. J. Virol. 81, 3807-3815.
15. Iwatani, Y., Chan, D. S., Liu, L., Yoshii, H., Shibata, J., Yamamoto, N., Levin, J. G., Gronenborn, A. M., and Sug-iura, W. (2009). HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 106,19539-19544.
16. Jarmuz, A., Chester, A., Bayliss, J., Gisbourne, J., Dunham, I., Scott, J., and Navaratnam, N. (2002). An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79, 285-296.
17. LaRue, R. S., Andresdottir, V., Blan-chard, Y., Conticello, S. G., Derse, D., Emerman, M., Greene, W. C., Jon-sson, S. R., Landau, N. R., Lochelt, M., Malik, H. S., Malim, M. H., Munk, C., O'Brien, S. J., Pathak, V K., Strebel, K., Wain-Hobson, S., Yu, X. F.,Yuhki,N.,and Harris,R.S. (2009). Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 83, 494-497.
18. Li, M. M., Wu, L. I., and Emerman, M. (2010). The range of human APOBEC3H sensitivity to lentiviral Vif proteins.J. Virol. 84, 88-95.
19. Mangeat, B., Turelli, P., Liao, S., and Trono, D. (2004). A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279,14481-14483.
20. Miyagi, E., Brown, C. R., Opi, S., Khan, M., Goila-Gaur, R., Kao, S., Walker, R. C. Jr., Hirsch, V., and Strebel, K. (2010). Stably expressed APOBEC3F has negligible antiviral activity. J. Virol. 84, 11067-11075.
21. OhAinle, M., Kerns, J. A., Li, M. M., Malik, H. S., and Emerman, M. (2008). Antiretroelement activity of APOBEC3H was lost twice in recent human evolution. Cell Host Microbe 4, 249-259.
22. Pery, E., Rajendran, K. S., Brazier, A. J., and Gabuzda, D. (2009). Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. J. Virol. 83, 2374-2381.
23. Russell, R. A., and Pathak, V K. (2007). Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. J. Virol. 81, 8201-8210.
24. Schrofelbauer, B., Chen, D., and Landau, N. R. (2004). A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U.S.A. 101, 3927-3932.
25. Schrofelbauer, B., Senger, T., Manning, G., and Landau, N. R. (2006). Muta-tional alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with non-human primate APOBEC3G. J. Virol. 80,5984-5991.
26. Shandilya, S. M., Nalam, M. N., Nalivaika, E. A., Gross, P. J., Valesano, J. C., Shindo, K., Li, M., Munson, M., Royer, W E., Harjes, E., Kono, T., Matsuo, H., Harris, R. S., Somasundaran, M., and Schiffer, C. A. (2010). Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 18, 28-38.
27. Sheehy, A. M., Gaddis, N. C., Choi, J. D., and Malim, M. H. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650.
28. Shirakawa, K., Takaori-Kondo, A., Yokoyama, M., Izumi, T., Matsui, M., Io, K., Sato, T., Sato, H., and Uchiyama, T. (2008). Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat. Struct. Mol. Biol. 15, 1184-1191.
29. Simon, V., Zennou, V., Murray, D., Huang, Y., Ho, D. D., and Bieniasz, P. D. (2005). Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoSPathog. 1,e6. doi:10.1371/journal.ppat.0010006
30. Smith, J. L., and Pathak, V K. (2010). Identification of specific determinants of human APOBEC3F, APOBEC3C, and APOBEC3DE and African green monkey APOBEC3F that interact with HIV-1 Vif. J. Virol. 84,12599-12608.
31. Tan, L., Sarkis, P. T., Wang, T., Tian, C., and Yu, X. F. (2009). Sole copy ofZ2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEBJ. 23,279-287.
32. Tian, C., Yu, X., Zhang, W., Wang, T., Xu, R., and Yu, X. F. (2006). Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. J. Virol. 80, 3112-3115.
33. Wang, Y., Shao, Q., Yu, X., Kong, W., Hildreth, J. E., and Liu, B. (2011). N-terminal hemagglutinin tag renders lysine-deficient APOBEC3G resistant to HIV-1 Vif-induced degradation by reduced polyubiquitination. J. Virol. 85,4510-4519.
34. Wedekind, J. E., Dance, G. S., Sowden, M. P., and Smith, H. C. (2003). Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business. Trends Genet. 19, 207-216.
35. Wiegand, H. L., Doehle, B. P., Bogerd, H. P., and Cullen, B. R. (2004). A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO J.23,2451-2458.
36. Xu, H., Svarovskaia, E. S., Barr, R., Zhang, Y., Khan, M. A., Strebel, K., and Pathak, V K. (2004). A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U.S.A. 101, 5652-5657.
37. Yu, X., Yu, Y., Liu, B., Luo, K., Kong, W., Mao, P., and Yu, X. F. (2003). Induction of APOBEC3G ubiquiti-nationand degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302, 1056-1060.
38. Yu, X. F. (2006). Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr. Opin. HIV AIDS 1,187-193.
39. Zhang, W., Chen, G., Niewiadomska, A. M., Xu, R., and Yu, X. F. (2008). Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS ONE 3, e3963. doi:10.1371/jour-nal.pone.0003963
40. Zhen, A., Wang, T., Zhao, K., Xiong, Y., and Yu, X. F. (2010). A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. J. Virol. 84, 1902-1911.
41. Zheng, Y H., Irwin, D., Kurosu, T., Tokunaga, K., Sata, T., and Peterlin, B. M. (2004). Human APOBEC3F is another host factor that blocks human immunod-eficiency virustype1replication. J. Virol. 78, 6073-6076.